WeVote
Log In

Bill

Bill

SB 1552

Experimental Treatments for Terminal Conditions and Life-threatening Rare Diseases

2026 Regular Session Introduced by Danny Burgess

Florida bill expands experimental treatment access for terminal and rare disease patients outside FDA approval, balancing patient hope against safety regulation concerns.

Introduced
#andsolicitations
0
WeVote Research Nonpartisan
Bill Summary · SB 1552

Legislative bill overview

SB 1552 would expand access to experimental medical treatments for patients with terminal conditions or life-threatening rare diseases who have exhausted standard treatment options. The bill creates a pathway for compassionate use of unapproved drugs, biologics, and devices outside traditional FDA approval processes. This is sometimes called "right-to-try" legislation, allowing terminally ill patients to attempt experimental therapies that haven't completed full clinical trials.

Why is this important

For patients with rare diseases or terminal diagnoses, standard treatment options may be limited or ineffective, and waiting for FDA approval can mean running out of time. This bill could provide hope and access to potentially life-saving treatments years before they might otherwise become available. However, it also raises questions about patient safety, informed consent, and whether experimental treatments—which may be ineffective or harmful—should be more easily accessible outside rigorous testing frameworks.

Potential points of contention

  • Safety vs. access tradeoff: Experimental treatments lack the safety and efficacy data that FDA trials provide; expanding access could expose vulnerable patients to harmful therapies while potentially delaying their pursuit of established options
  • Equity and affordability concerns: Manufacturers may charge high prices for experimental treatments since there's no competition; patients without resources might be unable to access options while others can afford them
  • Research impact: Allowing compassionate use outside clinical trials could reduce patient enrollment in formal studies, potentially slowing the scientific evidence-gathering needed to bring treatments to broader populations or identify serious side effects

Compiled from official sources — confirm details with the bill’s official record.

Sign in to ask a question.